Gilead ended a phase 2/3 trial of long-acting HIV pills after the FDA maintained clinical hold restrictions on parts of the program. The company discontinued safety follow-up for the Wonders-2 study, which evaluated investigational integrase and capsid inhibitors against Biktarvy. Gilead said the earlier issue involved low CD4+ T-cell counts and reduced white blood cell counts in some participants; the company reported these measures returned toward baseline for the enrolled cohort, but the FDA hold remains in place. The move reinforces how regulatory constraints can truncate timelines and reshape HIV pipeline prioritization even when safety signals partially normalize.